Volume 14, Issue 12, Pages (November 2013)

Slides:

Advertisements

Similar presentations

Peri-operative FOLFOX4 chemotherapy and surgery for resectable liver metastases from colorectal cancer Long-term survival results of the EORTC Intergroup.

Advertisements

EORTC Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM) Interim results of the EORTC.

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Volume 14, Issue 4, Pages (April 2013)

Volume 386, Issue 10006, Pages (November 2015)

Volume 385, Issue 9980, Pages (May 2015)

Volume 12, Issue 9, Pages (September 2011)

Volume 16, Issue 2, Pages (February 2015)

Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled.

Volume 12, Issue 11, Pages (October 2011)

Volume 376, Issue 9747, Pages (October 2010)

Volume 388, Issue 10058, Pages (November 2016)

Volume 15, Issue 6, Pages (May 2014)

The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis K.

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9779, Pages (May 2011)

Volume 377, Issue 9783, Pages (June 2011)

Volume 13, Issue 12, Pages (December 2012)

Volume 12, Issue 8, Pages (August 2011)

Volume 16, Issue 8, Pages (August 2015)

Volume 15, Issue 4, Pages (April 2014)

Aspirin in the prevention of cancer – Author's reply

Volume 14, Issue 10, Pages (September 2013)

Volume 374, Issue 9707, Pages (December 2009)

Volume 10, Issue 6, Pages (June 2009)

Volume 15, Issue 4, Pages (April 2014)

Surgery versus conservative management for recurrent and ongoing left-sided diverticulitis (DIRECT trial): an open-label, multicentre, randomised controlled.

Volume 366, Issue 9484, Pages (August 2005)

Volume 386, Issue 9999, Pages (September 2015)

Volume 12, Issue 7, Pages (July 2011)

Volume 378, Issue 9800, Pages (October 2011)

Volume 379, Issue 9812, Pages (January 2012)

Volume 15, Issue 1, Pages (January 2014)

Volume 356, Issue 9241, Pages (November 2000)

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Volume 13, Issue 12, Pages (December 2012)

Volume 6, Issue 6, Pages (June 2005)

Volume 14, Issue 11, Pages (October 2013)

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Volume 18, Issue 3, Pages (March 2017)

Volume 385, Issue 9962, Pages (January 2015)

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,

Volume 388, Issue 10058, Pages (November 2016)

Volume 371, Issue 9627, Pages (May 2008)

Volume 9, Issue 4, Pages (April 2008)

Volume 15, Issue 6, Pages (May 2014)

Volume 14, Issue 6, Pages (May 2013)

Volume 5, Issue 4, Pages (April 2018)

Volume 16, Issue 8, Pages (August 2015)

Volume 373, Issue 9658, Pages (January 2009)

Volume 15, Issue 6, Pages (May 2014)

ACST: which subgroups will benefit most from carotid endarterectomy?

Volume 11, Issue 1, Pages (January 2010)

Volume 371, Issue 9618, Pages (March 2008)

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

Volume 375, Issue 9715, Pages (February 2010)

Volume 376, Issue 9747, Pages (October 2010)

Volume 14, Issue 9, Pages (August 2013)

Volume 13, Issue 7, Pages (July 2014)

It’s All in the “Swerve of the Curve”

Pulmonary Resection for Metastases from Colorectal Cancer

Interferon alfa-2a for melanoma metastases

Volume 14, Issue 7, Pages (June 2013)

Volume 371, Issue 9617, Pages (March 2008)

A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung.

Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial R.S Keresztes, MD, J.L Port, MD, M.W Pasmantier,

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Volume 14, Issue 12, Pages 1208-1215 (November 2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial Prof Bernard Nordlinger, MD, Prof Halfdan Sorbye, MD, Prof Bengt Glimelius, MD, Prof Graeme J Poston, MD, Prof Peter M Schlag, MD, Prof Philippe Rougier, MD, Prof Wolf O Bechstein, MD, Prof John N Primrose, MD, Euan T Walpole, MBBS, Meg Finch-Jones, MD, Prof Daniel Jaeck, MD, Darius Mirza, FRCS, Rowan W Parks, MD, Murielle Mauer, PhD, Erik Tanis, MD, Prof Eric Van Cutsem, MD, Prof Werner Scheithauer, MD, Thomas Gruenberger, MD The Lancet Oncology Volume 14, Issue 12, Pages 1208-1215 (November 2013) DOI: 10.1016/S1470-2045(13)70447-9 Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile *37 patients who had a tumour resection were not given postoperative chemotherapy; 68 of all patients assigned to perioperative chemotherapy were not given postoperative chemotherapy. The Lancet Oncology 2013 14, 1208-1215DOI: (10.1016/S1470-2045(13)70447-9) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 2 Overall survival Kaplan-Meier curves of overall survival in all randomly assigned patients (A) and all eligible patients (B) per treatment group. The Lancet Oncology 2013 14, 1208-1215DOI: (10.1016/S1470-2045(13)70447-9) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 3 Progression-free survival (long-term update) Kaplan-Meier curves of progression-free survival in all randomly assigned patients (A) and all eligible patients (B) per treatment group. The Lancet Oncology 2013 14, 1208-1215DOI: (10.1016/S1470-2045(13)70447-9) Copyright © 2013 Elsevier Ltd Terms and Conditions